Alnylam After the Crash: Is the RNAi Pioneer an Investment Opportunity?

Alnylam After the Crash: Is the RNAi Pioneer an Investment Opportunity?

An investor-focused analysis of Alnylam Pharmaceuticals (NASDAQ: ALNY), July 31, 2026

Alnylam Pharmaceuticals shares plunged 28.3% on July 30, closing at $205.48, down from the previous day’s close of $286.62, after the company reported second-quarter results. At first glance, the reaction looks astonishing. Total revenue rose 67% from a year earlier. Sales of AMVUTTRA, the company’s flagship medicine, more than doubled and passed $1 billion in a single quarter for the first time. Alnylam earned a GAAP profit of $164.5 million instead of the $72.2 million loss recorded a year earlier. Non-GAAP earnings of $1.84 per share comfortably exceeded the approximately $1.60 consensus estimate. Yet roughly $11 billion of market value disappeared in a day.

The selloff was not really about an earnings miss. Investors had been valuing Alnylam based not on its current earnings, but on expectations for an exceptionally rapid launch of AMVUTTRA in a potentially enormous new heart-disease market. Total revenue of $1.291 billion came in modestly below the approximately $1.32 billion analysts expected, and when management simultaneously reduced its 2026 sales forecast and acknowledged that part of the early launch had come from a temporary backlog of patients waiting for the drug, the market abruptly lowered its assumptions about the future. The earnings beat, in other words, was irrelevant to the selloff; the revenue shortfall and the guidance cut were the whole story.

This distinction is central to the investment case. The quarter did not show that AMVUTTRA had stopped growing, that its clinical evidence had weakened, or that a competitor had displaced it. It showed that its growth path will probably be less explosive and less predictable than investors had assumed. At approximately $205 per share, Alnylam is far less expensive than it was two days earlier — but it is not an obviously cheap biotechnology stock. It is now a profitable, high-growth biopharmaceutical company with a strong scientific platform, a valuable lead franchise, a promising pipeline, and substantial concentration and execution risk.

What Alnylam Actually Does

Alnylam was founded to turn RNA interference, usually abbreviated RNAi, into medicines. RNAi is a natural process cells use to regulate protein production. Genes contain instructions, but DNA itself normally stays protected inside the cell’s nucleus. When a cell needs to make a protein, it produces a temporary working copy of the relevant instruction called messenger RNA, or mRNA. A cellular machine reads that mRNA and builds the protein.

An RNAi medicine is designed to recognize the mRNA for one particular protein. Once inside the appropriate cell, the drug guides a natural molecular complex to cut that mRNA. The cell therefore makes much less of the targeted protein. In plain language, the therapy intercepts the recipe before the harmful protein is produced.

This is different from a conventional small-molecule drug, which commonly binds to a protein after it has already been made. It is also different from gene editing: an RNAi drug does not permanently alter the patient’s DNA. Its effect can be long-lasting, but it eventually wears off and another dose is required.

The scientific attraction is specificity. If researchers know that an excessive or abnormal protein causes disease, they can design a short interfering RNA, or siRNA, to silence the corresponding message. The principal practical challenge is delivery. Unprotected RNA is rapidly degraded and does not readily enter the right cells. Alnylam’s decisive achievement was learning how to chemically stabilize these molecules and deliver them, initially to liver cells. Several of its newer programs attempt to reach the central nervous system and other tissues, which could greatly expand the platform’s value but also introduces new scientific risk.

Alnylam has produced six FDA-approved medicines discovered through its platform. It directly sells four — AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO — and receives collaboration or royalty income from partner-marketed LEQVIO and QFITLIA. This record makes RNAi a validated drug technology rather than a theoretical experiment.

AMVUTTRA and the Disease Behind the Investment Story

AMVUTTRA, or vutrisiran, accounts for nearly all of Alnylam’s present growth. It treats transthyretin amyloidosis, a progressive disease in which a normally useful blood protein called transthyretin, or TTR, becomes unstable, misfolds and accumulates as amyloid deposits in tissues.

TTR is made mainly in the liver and normally transports thyroid hormone and vitamin A–associated proteins. In hereditary ATTR, a mutation makes the protein more prone to misfolding. In wild-type ATTR, the normal protein becomes unstable with age. Amyloid can accumulate around nerves, causing pain, numbness, weakness and autonomic problems — the polyneuropathy form, ATTR-PN. It can also stiffen and damage the heart muscle, causing heart failure and rhythm problems — the cardiomyopathy form, ATTR-CM. Some patients have both.

AMVUTTRA is a small interfering RNA conjugated to GalNAc, a sugar-based delivery tag that liver cells efficiently absorb. Once inside those cells, it destroys TTR messenger RNA and sharply reduces production of both mutant and normal TTR. It is administered by a healthcare professional as a subcutaneous injection once every three months. Because TTR helps transport vitamin A, patients require vitamin A supplementation, and reduced vitamin A is an expected biological effect of treatment.

AMVUTTRA was originally approved for hereditary ATTR polyneuropathy. Its commercial opportunity changed dramatically in March 2025, when the FDA expanded approval to adults with hereditary or wild-type ATTR cardiomyopathy to reduce cardiovascular death, cardiovascular hospitalization and urgent heart-failure visits. Cardiomyopathy is a much larger population than hereditary polyneuropathy and remains substantially underdiagnosed.

The approval rested on HELIOS-B, a 655-patient Phase 3 trial. Vutrisiran reduced the combined risk of death from any cause and recurrent cardiovascular events by 28% in the overall population, and by a larger margin — roughly a third — among patients who weren’t already on a TTR stabilizer at the study’s start. It also improved or slowed deterioration in walking capacity, symptoms and quality of life, and a later secondary analysis published in Nature Medicine showed vutrisiran attenuated the decline in heart structure and function seen on echocardiogram. Importantly, the study included a contemporary population: some patients were already taking tafamidis, Pfizer’s TTR stabilizer. The FDA label reports no new major safety signal in the cardiomyopathy study, although low vitamin A levels were common.

AMVUTTRA’s principal competitors use a different strategy. Pfizer’s tafamidis products, Vyndaqel and Vyndamax, and BridgeBio’s acoramidis, sold as Attruby, stabilize the TTR protein after it is produced so that it is less likely to fall apart and form amyloid. AMVUTTRA reduces the quantity of TTR made in the first place. That mechanistic difference is commercially meaningful, but it does not automatically prove that every patient should receive AMVUTTRA or that silencing is clinically superior to stabilization. There are no simple head-to-head outcome trials proving that proposition.

The market may ultimately include monotherapy with either a stabilizer or silencer and combination treatment for selected patients. Combination use could enlarge Alnylam’s opportunity, but its value is still uncertain because adding two costly therapies must be justified to physicians and payers. In a 2025 assessment, the Institute for Clinical and Economic Review found substantial benefits from both approaches but noted disagreement about whether evidence clearly established the incremental value of adding vutrisiran to tafamidis. That is a reimbursement risk investors should not ignore.

One competitive threat receded, though perhaps not permanently. In July 2026, AstraZeneca and Ionis reported that eplontersen, another TTR-lowering medicine marketed as Wainua for polyneuropathy, missed the primary endpoint of its Phase 3 cardiomyopathy trial, CARDIO-TTRansform, in the overall study population. That’s a meaningful setback for a would-be rival — but the companies also reported that a prespecified subgroup of patients taking Wainua as monotherapy, without a background stabilizer, showed a nominally significant reduction in cardiovascular events, while those already on a stabilizer showed no added benefit. AstraZeneca and Ionis plan to present the full dataset at the European Society of Cardiology Congress in August 2026, and that presentation could reopen the question of whether eplontersen has a future in first-line cardiomyopathy. For now, Alnylam remains the only approved gene-silencing option in ATTR-CM, but investors should treat that exclusivity as provisional rather than settled. Longer term, competitors also include other silencers and potentially one-time gene-editing treatments. Alnylam is also developing its own successor, nucresiran, partly to prevent its franchise from being technologically leapfrogged.

Why the Stock Imploded

Alnylam reported second-quarter product sales of $1.172 billion, up 74% year over year. AMVUTTRA generated $1.012 billion, up from $492 million a year earlier. Total TTR-franchise revenue, including the older ONPATTRO, reached $1.030 billion, up 89%. Total revenue of $1.291 billion, however, came in below the approximately $1.32 billion analysts had modeled, a shortfall of a few percent.

The disappointment was concentrated in the forecast, not the quarter itself. Management reduced expected 2026 TTR product revenue from $4.4–$4.7 billion to $4.2–$4.5 billion. Total product-revenue guidance fell from $4.9–$5.3 billion to $4.7–$5.1 billion. A $200 million reduction at the midpoint is only about 4% of the prior TTR forecast, but it contradicted the market’s assumption that estimates would keep rising. Working in the other direction, Alnylam simultaneously raised its guidance for collaboration and royalty revenue to $575–625 million from a prior $400–500 million, a $150 million increase at the midpoint that CFO Jeffrey Poulton attributed largely to higher royalties from Novartis’s LEQVIO sales and greater cost reimbursement from Roche tied to enrollment in the ZENITH Phase 3 hypertension trial. That offset is real, but it wasn’t nearly large enough to blunt the market’s reaction to the core franchise cut.

Management divided the cardiomyopathy launch into first-line and second-line use. First-line patients begin AMVUTTRA as their initial disease-modifying therapy. Second-line patients switch from, or add it after, a stabilizer. At launch, many patients whose disease was progressing on stabilizers had already been waiting for a silencer. Their rapid movement onto AMVUTTRA created pent-up second-line demand. Once that waiting pool was treated, second-line growth normalized more sharply than Alnylam had built into its forecast. On the earnings call, CFO Poulton was candid about the miscalculation, saying the company “didn’t get it right” with its original guidance.

This is not the same as losing existing patients or suffering a clinical failure. Management said roughly 80% of new cardiomyopathy starts were first-line, and estimated that approximately 80% of U.S. ATTR-CM patients remained untreated. Those figures support a long runway, but investors must now demand evidence in coming quarters that first-line patient finding can replace the exhausted switch backlog.

The severity of the stock reaction reflected valuation and expectations more than the numbers themselves. Before earnings, the shares had closed at $286.62 and had benefited recently from the failure of Wainua’s cardiomyopathy trial. At the post-crash close of $205.48, Alnylam’s market capitalization fell to roughly $27–28 billion. The market erased far more value than a $200 million reduction in annual guidance would seem to justify, because a launch-curve change affects estimates for many future years, not only 2026. It also damages confidence in management’s visibility only months after the company had been reiterating a higher forecast.

The Rest of the Commercial Portfolio

ONPATTRO, or patisiran, was the first FDA-approved RNAi therapeutic and also lowers TTR. It is administered by intravenous infusion and treats hereditary ATTR polyneuropathy. AMVUTTRA’s convenient quarterly injection has made it the natural successor. ONPATTRO sales fell 65% to $18 million in the second quarter. That decline is expected product replacement, not evidence that the TTR franchise itself is shrinking.

GIVLAARI, or givosiran, treats acute hepatic porphyria, a group of rare genetic liver disorders in which toxic intermediates in heme production accumulate and can cause severe abdominal pain, neurological symptoms and potentially life-threatening attacks. GIVLAARI silences the messenger RNA for ALAS1, an upstream liver enzyme, thereby reducing production of those toxic intermediates. It is injected monthly. Second-quarter sales rose 11% to $89.8 million.

OXLUMO, or lumasiran, treats primary hyperoxaluria type 1, a rare inherited liver disorder that causes excessive oxalate production. Oxalate combines with calcium to form crystals that damage the kidneys and, in severe disease, other organs. OXLUMO silences HAO1, which encodes an enzyme upstream of oxalate production. Second-quarter sales rose 11% to $52.1 million.

These medicines are valuable and growing, but together GIVLAARI and OXLUMO produced only $142 million in the quarter, compared with more than $1 billion from the TTR franchise. They provide diversification, but not enough to offset an AMVUTTRA disappointment.

Alnylam also benefits from partnered medicines. Novartis markets LEQVIO, or inclisiran, an Alnylam-discovered RNAi drug that lowers PCSK9 and therefore LDL cholesterol. Alnylam receives royalties, although it previously sold a portion of future LEQVIO royalties for cash, leaving a large financing liability on its balance sheet. Sanofi markets QFITLIA, or fitusiran, an RNAi medicine approved in 2025 for hemophilia A or B with or without inhibitors. It lowers antithrombin to rebalance blood clotting; Alnylam is eligible for tiered royalties on global sales. These partnered products validate the platform and add lower-cost revenue, but the economics are shared.

The Pipeline: Where the Next Sources of Value Could Come From

Nucresiran: defending the TTR franchise. Nucresiran is Alnylam’s next-generation TTR silencer. In Phase 1, a single 300 mg dose produced greater than 90% mean TTR reduction by day 15 and maintained substantial suppression for a year, supporting dosing as infrequently as every six months. Phase 3 TRITON trials are underway in cardiomyopathy and polyneuropathy, with targeted launches in polyneuropathy by 2028 and cardiomyopathy by 2030. Nucresiran is strategically important but should not be counted as entirely new revenue — some of its sales would replace AMVUTTRA rather than expand the franchise. Its real value is extending Alnylam’s leadership, improving convenience, and defending against future competitors.

Zilebesiran: the largest commercial idea, and a difficult one. Zilebesiran targets angiotensinogen, a liver-produced precursor in the renin-angiotensin system that regulates blood pressure. A twice-yearly injection could provide continuous control and solve one of hypertension’s biggest practical problems: patients frequently miss daily tablets. Alnylam and Roche are running ZENITH, an approximately 11,000-patient Phase 3 cardiovascular-outcomes trial in people whose hypertension remains uncontrolled despite at least two drugs and who have cardiovascular disease or high risk. Roche paid $310 million upfront under the partnership, with additional potential milestones reaching $2.8 billion. Generic blood-pressure pills are inexpensive and effective when taken correctly, so a premium injectable will likely need to show fewer heart attacks, strokes or cardiovascular deaths, not just lower office blood pressure. Zilebesiran deserves meaningful but probability-adjusted pipeline value, not automatic blockbuster credit.

Mivelsiran and CNS delivery. Mivelsiran targets amyloid precursor protein, or APP, upstream of the amyloid-beta fragments that accumulate in Alzheimer’s disease and in cerebral amyloid angiopathy, a disease of amyloid deposits in brain blood vessels that can cause hemorrhagic strokes. It is administered into the spinal fluid, allowing the RNAi drug to reach the central nervous system. Early data showed durable reductions in cerebrospinal-fluid biomarkers — at the highest dose, mean maximum reductions reached about 90% for soluble APP-beta and 70% for amyloid beta 42 — with no evidence so far of an increased risk of the amyloid-related brain swelling or bleeding abnormalities associated with anti-amyloid antibodies. Biomarker reduction is not yet proof that patients think, function or survive better, however. The Phase 2 cAPPricorn-1 cerebral amyloid angiopathy study is fully enrolled, with initial results expected in 2028, and a separate Phase 2 study has begun in Down syndrome–associated Alzheimer’s disease.

Huntington’s disease and tau. ALN-HTT02, partnered with Regeneron, is designed to lower the exon-1 fragment of huntingtin associated with Huntington’s disease. Initial Phase 1 patient data are scheduled for presentation at the European Huntington’s Disease Network Congress in October 2026. ALN-5288, also partnered with Regeneron, targets tau and entered Phase 1 in late 2025. At this stage it is an option on future science rather than a material component of a conservative valuation.

Metabolic and hematology programs. ALN-6400 lowers plasminogen, a protein involved in breaking down blood clots; reducing clot breakdown may help patients with certain bleeding disorders. The drug is being evaluated in hereditary hemorrhagic telangiectasia and von Willebrand disease. Phase 1 healthy-volunteer results and Phase 2 proof-of-concept results in HHT are expected in the second half of 2026, while the von Willebrand disease study is at an earlier stage. On the metabolic side, ALN-2232 is an early obesity candidate with Phase 1 results also expected in the second half of 2026, and ALN-4324, an RNAi candidate targeting the GRB14 gene, is in a Phase 2 trial testing its effect on insulin sensitivity in adults with type 2 diabetes — Alnylam has described it as a potential insulin sensitizer, a drug class that hasn’t seen a new approved entrant in decades. Both programs could eventually address very large markets, but the competitive bar is extraordinarily high given how effective existing incretin-based obesity and diabetes therapies already are. Investors should wait for human efficacy, safety and durability data before assigning large values.

Financial Quality: No Longer a Cash-Burning Biotech

Alnylam’s finances have changed fundamentally. In the first half of 2026, product revenue reached roughly $2.2 billion, nearly double the prior-year period. The company produced GAAP operating income and net income for the first half, compared with essentially break-even operations and a net loss a year earlier.

For the second quarter alone, GAAP net income was $164.5 million, versus a $72.2 million loss in the second quarter of 2025. Non-GAAP operating income was $318.1 million, more than triple the prior-year figure. Alnylam’s 2030 goal is a roughly 30% non-GAAP operating margin while continuing to invest heavily in research.

Operating leverage is visible but not effortless. R&D spending rose sharply as large Phase 3 trials accelerated, and cost of goods sold increased as a share of product revenue, partly because higher AMVUTTRA sales trigger a higher blended royalty rate. This means AMVUTTRA’s gross margin does not scale as cleanly as an entirely unencumbered internally owned drug.

The balance sheet held $3.3 billion of cash and marketable securities at June 30, up from $2.9 billion at year-end 2025. Against that are approximately $1.0 billion of convertible debt and $1.72 billion of liabilities associated with sold future royalties and outside development funding. The latter are economically important: prior financing gave investors claims on some future cash flows, particularly LEQVIO royalties, and generates real reported interest expense. Alnylam is liquid and now produces operating cash, so solvency is not the concern. The caution is that gross cash should not be treated as entirely excess cash when calculating enterprise value.

Share-based compensation and dilution also deserve attention. Alnylam recorded $86.6 million of stock-based compensation in the second quarter, and its outstanding share count increased from approximately 132.4 million at the end of 2025 to 133.7 million at June 30, 2026. That dilution is manageable relative to the company’s current growth, but stock-based compensation is a real economic cost to shareholders and helps explain part of the difference between GAAP and non-GAAP results.

One legal matter deserves ongoing monitoring. In October 2025, Alnylam received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts seeking documents about government price reporting for all four directly sold products, including distributor fee and discount arrangements. A subpoena does not establish wrongdoing, and no loss can presently be estimated from the disclosed information. Nonetheless, pharmaceutical price-reporting investigations can produce settlements, changes in commercial practices and reputational damage, and it should not be omitted from the risk assessment.

Valuation After the Fall

At approximately $205 per share, Alnylam is valued at roughly $27–28 billion. Using updated 2026 guidance, product sales should be $4.7–$5.1 billion, with another $575–$625 million of collaboration and royalty revenue. At the midpoints, the shares trade near 5 times expected 2026 total revenue.

That is a far more defensible valuation than the pre-earnings market capitalization near $39 billion, but it still embeds continued growth and expanding margins. A mature pharmaceutical company with limited growth would not necessarily deserve this sales multiple. Alnylam can justify it only if AMVUTTRA continues penetrating first-line cardiomyopathy, international launches progress, the company approaches its margin target and at least some pipeline assets mature into valuable products.

A useful way to think about valuation is through scenarios rather than a single price target. In a bear case, first-line AMVUTTRA uptake slows, stabilizers retain most new patients, combination reimbursement stays limited, and pipeline trials disappoint — the stock can fall further because current value still assumes durable growth. In a base case, AMVUTTRA continues strong but less spectacular growth, Alnylam reaches its revised 2026 range, diagnosis expands, nucresiran protects the franchise, and one or two pipeline programs advance credibly — the post-crash valuation can support attractive multi-year returns, though the recovery may be uneven. In a bull case, AMVUTTRA becomes the leading first-line ATTR-CM therapy and gains combination use, zilebesiran proves cardiovascular benefit, CNS delivery produces convincing clinical results, and operating margin approaches 30% — Alnylam becomes a top-tier large biotechnology company, making the selloff a major buying opportunity.

The key error would be to value every pipeline candidate at its theoretical market size. The more disciplined approach is probability adjustment. Nucresiran deserves the highest confidence because it uses a validated target and platform in a disease Alnylam already understands. Zilebesiran has promising human blood-pressure data but must prove hard cardiovascular outcomes. Mivelsiran has impressive biomarker effects but not yet clinical benefit. The earlier metabolic and neuroscience programs should receive only modest option value until human data mature.

What Investors Should Watch Next

The most important figures in the next two quarters are not headline EPS. Investors should track sequential U.S. TTR demand, the proportion of first-line AMVUTTRA starts, net patient additions, discontinuations, and inventory movements. If first-line demand keeps growing while second-line use stabilizes, management’s explanation of a temporary backlog will be supported. If growth decelerates again, the revised forecast may not be conservative enough.

International cardiomyopathy uptake is the next commercial test, though international pricing is generally lower and access takes time. Watch too for the full CARDIO-TTRansform dataset at the European Society of Cardiology Congress in August 2026, which will clarify whether eplontersen’s monotherapy signal is durable enough to re-enter the competitive conversation. Scientifically, the nearest major catalysts include ALN-6400 results in bleeding disorders, Phase 1 obesity data for ALN-2232, and the October 2026 ALN-HTT02 Huntington’s readout. Investors should also monitor enrollment and progress in the recently initiated Phase 2 trial of ALN-4324 in type 2 diabetes — but none is likely to matter as much in the near term as evidence about AMVUTTRA’s launch trajectory.

Investors should also monitor competitive prescribing data for Attruby and tafamidis, payer acceptance of AMVUTTRA alone and in combination, progress of the TRITON nucresiran trials, enrollment in ZENITH, and any update to the government investigation.

Investment Conclusion

Alnylam is one of the scientifically strongest independent biotechnology companies. The company has repeatedly converted RNA interference into approved, commercially useful medicines. AMVUTTRA has compelling Phase 3 evidence, a differentiated mechanism, convenient quarterly administration and exposure to a large underdiagnosed disease. The company is profitable, liquid and still growing at a rate few mature drug companies can match.

The selloff was nevertheless rational in direction, even if arguably excessive in size. Alnylam had been priced for near-perfect execution. Management’s guidance cut revealed that investors had mistaken a temporary pool of waiting switch patients for a fully sustainable launch rate. Because AMVUTTRA dominates present revenue, a small reduction in its assumed long-term curve produces a large change in equity value — and that dynamic, not a disappointing earnings print, is what drove the crash.

The central investment question is not whether RNAi works — it’s whether AMVUTTRA can become a broad, durable first-line heart medicine quickly enough, and whether the cash it generates can turn a scientifically rich pipeline into additional blockbusters without sacrificing financial discipline. The July collapse made that long-term investment proposition considerably less expensive.

*****